ICT received in rechallenged patients
| All patients (n=61) | ICT1 (%) n=61 | ICT2 (%) n=34 | ICT3 (%) n=7 |
| Anti-PD-(L)1 monotherapy | 7 (11) | 23 (68) | 2 (29) |
| Anti-CTLA-4 monotherapy | 10 (16) | 0 (0) | 0 (0) |
| Anti-CTLA-4+anti-PD-(L)1 | 23 (38) | 2 (6) | 1 (14) |
| Anti-PD-(L)1+TKI | 6 (10) | 6 (18) | 3 (43) |
| Anti-CTLA-4+anti-PD-(L)1+TKI | 1 (2) | 0 (0) | 0 (0) |
| Anti-PD(L)1+other | 14 (23) | 3 (9) | 1 (14) |
| Renal cell carcinoma (n=28) | ICT1 (%) n=28 | ICT2 (%) n=18 | ICT3 (%) n=5 |
| Anti-PD-(L)1 monotherapy | 3 (11) | 11 (61) | 1 (20) |
| Anti-CTLA-4 monotherapy | 1 (4) | 0 (0) | 0 (0) |
| Anti-CTLA-4+anti-PD-(L)1 | 10 (36) | 0 (0) | 1 (20) |
| Anti-PD-(L)1+TKI | 6 (21) | 6 (33) | 3 (60) |
| Anti-CTLA-4+anti-PD-(L)1+TKI | 1 (4) | 0 (0) | 0 (0) |
| Anti-PD(L)1+other | 7 (25) | 1 (6) | 0 (0) |
| Urothelial carcinoma (n=14) | ICT1 (%) n=14 | ICT2 (%) n=7 | ICT3 (%) n=2 |
| Anti-PD-(L)1 monotherapy | 4 (29) | 4 (57) | 1 (50) |
| Anti-CTLA-4 monotherapy | 3 (21) | 0 (0) | 0 (0) |
| Anti-CTLA-4+anti-PD-(L)1 | 3 (21) | 1 (14) | 0 (0) |
| Anti-PD(L)1+other | 4 (21) | 2 (28) | 1 (50) |
| Prostate cancer (n=19) | ICT1 (%) n=19 | ICT2 (%) n=9 | ICT3 (%) n=0 |
| Anti-PD-(L)1 monotherapy | 0 (0) | 8 (89) | 0 (0) |
| Anti-CTLA-4 monotherapy | 6 (32) | 0 (0) | 0 (0) |
| Anti-CTLA-4+anti-PD-(L)1 | 10 (53) | 0 (0) | 0 (0) |
| Anti-PD(L)1+other | 3 (16) | 1 (11) | 0 (0) |
*'ICT1’ refers to the first checkpoint therapy to which the patient was exposed, ‘ICT2’ the second, and ‘ICT3’ the third.
CTLA-4, cytotoxic T lymphocyte-associated protein-4; ICT, immune checkpoint therapy; PD-1, programmed cell death protein-1; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor.